News Headlines
-
Applied DNA Awarded Contract By HDT Bio For Rapid Vaccine Development Program
4/25/2024
Applied DNA Sciences, Inc. (Applied DNA), a leader in PCR-based DNA technologies, today announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler’ award to HDT Bio (the “Project”).
-
FibroBiologics Plans To Collaborate With Charles River To Manufacture Fibroblast-Based Spheroids
4/25/2024
FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.
-
Regeneron And Mammoth Biosciences Collaborate To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases
4/25/2024
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types.
-
Abzena Launches EpiScreen® 2.0 Immunogenicity Platform
4/25/2024
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.
-
ANGLE Plc Announces New Commercial Agreement With AstraZeneca
4/24/2024
ANGLE plc a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response ("DDR") assay for the detection of micronuclei in CTCs as a measure of DDR.
-
Kühne Holding Acquires Pharma Contract Manufacturer Aenova From BC Partners
4/24/2024
Kühne Holding AG has entered into a definitive agreement to acquire pharma contract development and manufacturing organization Aenova Group from leading international investment firm BC Partners. As part of the transaction, BC Partners’ advised funds will reinvest alongside Kühne Holding AG and continue to support Aenova as a minority shareholder.
-
Multiply Labs And GenScript Biotech Corporation Collaborate To Automate The Cell Isolation And Enrichment Phase Of Cell Therapy Manufacturing
4/23/2024
GenScript Biotech Corporation (GenScript), one of the world's leading providers of life-science research tools and services, and Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.
-
Evotec SE Appoints Dr Christian Wojczewski As Chief Executive Officer
4/23/2024
The Supervisory Board of Evotec SE has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.
-
Vertex And TreeFrog Therapeutics Announce Licensing Agreement And Collaboration To Optimize Production Of Vertex’s Cell Therapies For Type 1 Diabetes
4/23/2024
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-Stem, to optimize production of Vertex’s cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog’s process to produce and amplify cells for Vertex’s T1D therapies.
-
Hanmi Enters Into Clinical Trial Collaboration And Supply Agreement With MSD To Evaluate BH3120 In Combination With KEYTRUDA® (pembrolizumab)
4/23/2024
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA).